IL17A and Chronic mucocutaneous candidosis: Patients with the STAT1 mutation also have hindered the production of IL-17A, IL-17F, and IL-22 by T cells, and, therefore, these patients have impaired IL-17 immunity and are predisposed to chronic mucocutaneous candidiasis [73].